To amend the Chemical and Biological Weapons Control and Warfare Elimination Act of 1991 to impose sanctions on foreign countries in response to acts concerning chemical or biological programs that cause injury to other foreign countries, and for other purposes.
Summary
HR7552 is an early-stage bill amending the Chemical and Biological Weapons Control Act. It authorizes no funding, creates no procurement mechanism, and is stuck in committee referral with no floor action. Zero near-term market impact for retail investors.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7552 is purely a foreign policy sanctions authorization bill — it does not move money or create contracts.
- 2.No committee hearings, markups, or floor actions have occurred since referral on February 12, 2026.
- 3.The bill has zero impact on any publicly traded company's revenue or costs.
Market Implications
No market implications. The bill has no funding, no procurement mechanism, and is at the earliest legislative stage. Retail investors should ignore until the bill advances to committee markup or gains significant cosponsor momentum. No tickers are affected.
Full Analysis
HR7552, introduced February 12, 2026, is a bill in the 119th Congress that amends the Chemical and Biological Weapons Control and Warfare Elimination Act of 1991 to expand sanction triggers to include actions concerning chemical or biological programs that injure another country. The bill has a provocative short title branding it as anti-fentanyl legislation, but the actual text merely adds new presidential reporting requirements and sanction triggers. It does not authorize a single dollar of spending, create any contract vehicle, or mandate a specific regulatory action. The bill has been referred to the Committee on Foreign Affairs and two other committees since February 12 and has seen no further action. Its two cosponsors are junior members. The companion bill S63 is in the same procedural limbo. No investor action is warranted at this stage.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →